Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 7/20 | 0.68 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | PGR | P06401 | 3/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 7/20 | 0.66 |
| ▸ | SERPINA6 | P08185 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.66 |
| ▸ | BLM | P54132 | 4/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13573314 | 1.00 | SHBG (0.68) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL17424597 | 1.00 | SHBG (0.68) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL12085097 | 1.00 | SHBG (0.68) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL30171328 | 0.85 | SHBG (0.71) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL13146616 | 0.85 | SHBG (0.71) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL31095091 | 0.84 | HSD17B10 (0.62) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL11244016 | 0.83 | SHBG (0.65) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL17775781 | 0.83 | SHBG (0.76) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL8423521 | 0.82 | SHBG (0.67) | SHBGNR3C1ALDH1A1PGRADRA1A | |
| SCHEMBL10273321 | 0.82 | SHBG (0.49) | SHBGNR3C1ALDH1A1PGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796668-B2 | Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use | REATA PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160145200-A1 | NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE | REATA PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | US | disclosed |
| US-9233998-B2 | Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use | REATA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20120283450-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | REATA PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8258329-B2 | Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use | REATA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20100048887-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | REATA PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048887-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | PTGES, PTGS1, PTGES2 | SHBG 2465/4885NR3C1 266/4885ALDH1A1 609/4885 |
| US-20160145200-A1 | NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE | PTGES, LTB4R, LTB4R2 | SHBG 1604/4885NR3C1 259/4885ALDH1A1 1340/4885 |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | CYP4A11, HSD17B11, CYP21A2 | SHBG 70/4885NR3C1 118/4885ALDH1A1 386/4885 |
| US-20120283450-A1 | COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE | PTGES, PTGS1, PTGES2 | SHBG 2465/4885NR3C1 266/4885ALDH1A1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.